Evidence map›Paper›PMID 27941973›Full record

ArticlePloS one2016

Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.

Antonino Tuttolomondo, Domenico Di Raimondo, Chiara Bellia, Giuseppe Clemente, Rosaria Pecoraro, Carlo Maida, Irene Simonetta, Valerio Vassallo, Danilo Di Bona, Eliana Gulotta and 2 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04785755 (Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Egyptian Cirrhotic Patients With Ascites), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04785755 phase2completednot on this mapstarted 2017, after this paper: background citation

Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Egyptian Cirrhotic Patients With Ascites

TypeinterventionalSponsorHala Abd EL-Tawab Ibrahim RadwanRan2017 to 2020Enrolled90ConditionsHepatic AscitesArmsOral standard diuretics therapy, Hypertonic saline solution, Etilefrine
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Management of refractory cirrhotic ascites: challenges and solutions.Hepatic medicine : evidence and research · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Antonino TuttolomondoU.O.C di Medicina Interna e con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Università degli Studi di Palermo (Italy).
Domenico Di RaimondoU.O.C di Medicina Interna e con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Università degli Studi di Palermo (Italy).
Chiara BelliaSezione di Biochimica Clinica e Medicina Molecolare Clinica, Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Università degli Studi di Palermo U.O.C. CoreLab, Azienda Ospedaliera Universitaria Policlinico, Palermo, Italy.
Giuseppe ClementeU.O.C di Medicina Interna e con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Università degli Studi di Palermo (Italy).
Rosaria PecoraroU.O.C di Medicina Interna e con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Università degli Studi di Palermo (Italy).
Carlo MaidaU.O.C di Medicina Interna e con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Università degli Studi di Palermo (Italy).
Irene SimonettaU.O.C di Medicina Interna e con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Università degli Studi di Palermo (Italy).
Valerio VassalloU.O.C di Medicina Interna e con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Università degli Studi di Palermo (Italy).
Danilo Di BonaSchool and Chair of Allergology, Dipartimento delle Emergenze e Trapianti d'Organo, University of Bari, Italy.
Eliana GulottaDipartimento di Chirurgia Generale e d'Urgenza, Policlinico Universitario "Paolo Giaccone, University of Palermo, Italy.
Marcello CiaccioSezione di Biochimica Clinica e Medicina Molecolare Clinica, Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Università degli Studi di Palermo U.O.C. CoreLab, Azienda Ospedaliera Universitaria Policlinico, Palermo, Italy.
Antonio PintoU.O.C di Medicina Interna e con Stroke Care, Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S), Università degli Studi di Palermo (Italy).
University of Palermo · ITAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with chronic liver diseases are usually thin as a result of hypermetabolism and malnutrition expressed by reduced levels of leptin and impairment of other adyponectins such as visfatin.

aimsWe evaluated the metabolic and inflammatory effects of intravenous high-dose furosemide plus hypertonic saline solutions (HSS) compared with repeated paracentesis and a standard oral diuretic schedule, in patients with cirrhosis and refractory ascites.

methods59 consecutive cirrhotic patients with refractory ascites unresponsive to outpatient treatment. Enrolled subjects were randomized to treatment with intravenous infusion of furosemide (125-250mg⁄bid) plus small volumes of HSS from the first day after admission until 3 days before discharge (Group A, n:38), or repeated paracentesis from the first day after admission until 3 days before discharge (Group B, n: 21). Plasma levels of ANP, BNP, Leptin, visfatin, IL-1β, TNF-a, IL-6 were measured before and after the two type of treatment.

resultsSubjects in group A were observed to have a significant reduction of serum levels of TNF-α, IL-1β, IL-6, ANP, BNP, and visfatin, thus regarding primary efficacy endpoints, in Group A vs. Group B we observed higher Δ-TNF-α, Δ-IL-1β, Δ-IL-6, Δ-ANP, Δ-BNP, Δ-visfatin, Δ-Leptin at discharge. DISCUSSION: Our findings underline the possible inflammatory and metabolic effect of saline overload correction in treatment of cirrhosis complications such as refractory ascites, suggesting a possible role of inflammatory and metabolic-nutritional variables as severity markers in these patients.

Indexed as

Administration, IntravenousAgedAscitesBiomarkersCytokinesDiureticsFemaleFurosemideHumansInflammation MediatorsLiver CirrhosisMaleMiddle AgedRecurrenceSaline Solution, HypertonicTreatment OutcomeBiomarkersCytokinesDiureticsFurosemideInflammation MediatorsSaline Solution, Hypertonic

Identifiers

PMID27941973
PMCPMC5152809
OpenAlexW2567563899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.